Key clinical point: The recombinant factor VIII turoctocog alfa effectively prevented and stopped bleeds in previously untreated children with hemophilia A.
Major finding: Of 58 prophylactically treated patients, 25 (43.1%) developed factor VIII inhibitors in the first 50 exposure days.
Study details: Results of guardian 4, a multinational, nonrandomized, phase 3 clinical trial including 60 pediatric patients with hemophilia A.
Disclosures: Novo Nordisk sponsored the guardian 4 study. The lead author reported disclosures related to Novo Nordisk, Shire, Bayer, and Octapharma.
Yaish HM et al. Haemophilia. 2019 Dec 9. doi: 10.1111/hae.13883.